Our prior study centered on contrasting the levels of IFN-γ among MS patients, untreated progressive MS (pMS) patients, and healthy controls (HCs), uncovering a reduced immune activation in MS patients, especially pronounced in those treated with fingolimod, a known suppressor of IFN-γ production. The gene discussed is IFNG; the disease is myeloid sarcoma.